"LiverColor": Machine Learning in Liver Photographs
"LiverColor": AN ALGORITHM QUANTIFICATION OF LIVER GRAFT STEATOSIS USING MACHINE LEARNING AND COLOR IMAGE PROCESSING
1 other identifier
interventional
246
1 country
1
Brief Summary
The main goal of this project is to create a machine learning model in order to quantify liver steatosis in liver donor faster, more objective and reliable than histological analysis and surgeons point-of-view.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Jun 2018
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 30, 2018
CompletedFirst Submitted
Initial submission to the registry
June 8, 2021
CompletedFirst Posted
Study publicly available on registry
January 24, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2023
CompletedJanuary 24, 2022
January 1, 2022
5.5 years
June 8, 2021
January 20, 2022
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
The main goal of this project is to create a machine learning model in order to quantify liver steatosis in liver donor faster, more objective and reliable than histological analysis and surgeons point-of-view.
Accuracy
4 weeks
Secondary Outcomes (1)
To build an image dataset to evaluate postransplant liver function.
1 week
Study Arms (1)
Liver from deceased donors
EXPERIMENTALThis study included all consecutive subjects with chronic liver disease who underwent LT for the first time with a deceased donor liver
Interventions
Eligibility Criteria
You may not qualify if:
- Age \< 18 years old
- Donor after cardiac death
- Split
- Cholestasis due to a biliary obstruction
- Total bilirubin levels above 2,5 mg/dL
- Glutamic oxaloacetic transaminase (SGOT)/ serum glutamatepyruvate transaminase (SGPT) levels and gamma-glutamyl transaminase (GGT) levels above 400 U/L
- Cirrhotic livers
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Concepción Gómez-Gavara
Barcelona, Spain
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Concepcion Gómez-Gavara, PhD
Vall D´Hebron University Hospital
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- DIAGNOSTIC
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- PhD
Study Record Dates
First Submitted
June 8, 2021
First Posted
January 24, 2022
Study Start
June 30, 2018
Primary Completion
December 31, 2023
Study Completion
December 31, 2023
Last Updated
January 24, 2022
Record last verified: 2022-01
Data Sharing
- IPD Sharing
- Will not share